ASDr. Ahmed ShihabConsultant Anesthesiologist – Baghdad عربي

A Guide to Neuromuscular Blocking Drugs and Reversal Agents in Clinical Anaesthesia

Topic notes · Basic Sciences · Anaesthetic drugs

Neuromuscular blocking drugs are among the mainstays of anaesthetic practice for securing the airway and facilitating surgical procedures. This article reviews the pharmacological properties of depolarising and non-depolarising neuromuscular blockers, as well as modern mechanisms for reversing the block.

The Depolarising Relaxant: Succinylcholine and Clinical Considerations

Succinylcholine binds to the alpha subunits of the nicotinic acetylcholine receptors, producing sustained depolarisation of the motor end plate that ends in fasciculations followed by complete muscle flaccidity. Its intubating dose is 1.0–1.5 mg/kg, while its ED95 is approximately 0.3 mg/kg. The drug has important side effects, including sinus bradycardia, junctional rhythm, fibrillation, muscle pains, raised intra-ocular and intragastric pressure, and masseter spasm. It is metabolised in plasma by the enzyme butyrylcholinesterase, and the dibucaine number test determines the efficiency of the enzyme; the normal value is 70–80% (block of 5–10 minutes), in heterozygotes it is 50–60% (block of 20 minutes), whereas in atypical homozygotes it falls to 20–30%, prolonging paralysis to between 60–180 minutes. Its administration is prohibited in burns, trauma and denervation of more than 24 hours, and in prolonged immobilisation, to avoid fatal hyperkalaemia, in addition to its propensity to trigger malignant hyperthermia and in myopathies such as Duchenne disease.

Non-Depolarising Relaxants and Methods of Their Elimination

Non-depolarising blockers are divided into several chemical classes; both rocuronium and vecuronium belong to the aminosteroid group. Rocuronium is given at an intubating dose of 0.6–1.2 mg/kg (with an ED95 of 0.30 mg/kg), and most of it is excreted unchanged via the liver. For vecuronium, the intubating dose is 0.08–0.1 mg/kg, and its metabolite 3-desacetylvecuronium is distinguished by having a blocking potency equal to 50–70% of the parent drug. On the other hand, the benzylisoquinoline compounds are distinguished by a self-elimination pathway that is independent of organs and non-enzymatic, called Hofmann elimination, which accelerates with rising temperature and pH; cisatracurium undergoes this pathway at a rate of 77% without releasing histamine, whereas the breakdown of atracurium is accompanied by histamine release and production of the metabolite laudanosine.

Strategies for Reversing Neuromuscular Block

Two pharmacological strategies are available for reversing the effect of muscle relaxants. The first is the classical one, using neostigmine, which reversibly inhibits the enzyme acetylcholinesterase to increase the concentration of acetylcholine, and which must be given together with glycopyrrolate or atropine to avoid acute muscarinic effects such as bradycardia and bronchoconstriction. The second, modern strategy is sugammadex, a modified gamma-cyclodextrin molecule that encapsulates and traps steroidal muscle relaxants within its cavity at a ratio of 1:1 to form an inactive complex that is excreted through the kidneys, with an order of affinity starting from rocuronium, then vecuronium, and much more weakly with pancuronium.

Key points
  • Succinylcholine is contraindicated 24 hours after burns, trauma and spinal cord injuries because of the risk of fatal hyperkalaemia resulting from receptor up-regulation.
  • The prolonged block with Succinylcholine (60–180 minutes) is attributed to a homozygous mutation of the plasma enzyme with a dibucaine number of 20–30%.
  • Cisatracurium breaks down at a rate of 77% by non-enzymatic Hofmann reaction without causing histamine release.
  • Sugammadex encapsulates aminosteroid molecules (especially Rocuronium and Vecuronium) at a ratio of 1:1 so that they are excreted by the kidneys.
  • Antimuscarinics such as Glycopyrrolate or Atropine must be co-administered with Neostigmine to prevent bradycardia and bronchoconstriction.

Sources

  • Miller's Basics of Anesthesia, 8th ed., p. 165
  • Miller's Basics of Anesthesia, 8th ed., p. 166
  • Pharmacology and Physiology for Anesthesia, p. 141
  • Pharmacology and Physiology for Anesthesia, p. 150

Test yourself: 5 questions on this topic and many more →

Educational content for healthcare staff and students. It does not replace clinical judgement or your hospital protocol; check any dose against the reference and local guidance before use.